In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow

Can String Of Deals Last?

Executive Summary

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

You may also be interested in...



Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction

Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.

China Respiratory Disease Surge Prompts WHO Info Request

Since October, reported cases of infectious respiratory diseases have been rising in China, prompting an information request from the WHO. However, no new types of pathogen or unusual clinical symptoms have been detected so far.

Chinese Language Podcast: 创新药美国获批, AI新药研发, 三季度业绩和中美峰会

Topics in this latest Chinese-language podcast include the US approval of Chinese innovative drugs including Junshi’s anti-PD-1 antibody toripalimab, Sanofi’s deal with BioMap for AI-powered drug discovery, Chinese companies' third-quarter results and the Biden-Xi summit on the sidelines of APEC and its implications for bilateral regulatory dialog.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel